OncLiveImmunotherapy Combinations Poised to Shift Standard of Care in RCCOncLiveOncLive: Please provide an overview of your presentation at this meeting. Hammers: I discussed immunotherapy combinations. It is an exciting time because it is expected tha… Continue reading
OncLiveCan Immunotherapy in HER2+ Breast Cancer Suppress Trastuzumab Resistance?Cancer NetworkThe combination of pembrolizumab and trastuzumab showed promising clinical benefit in patients with trastuzumab-resistant HER2-positive advanced breast cancer… Continue reading
OncLiveDr. Daniels on Immunotherapy in Head and Neck CancerOncLiveGregory A. Daniels, MD, PhD, medical oncologist, associate professor of medicine, UC San Diego Health, discusses the role of immunotherapy for patients with head and neck cancer. Accordi… Continue reading
Seeking AlphaYou Get A Dilution! You Get A Dilution! What About CRISPR Therapeutics?Seeking AlphaThe recent secondary offerings from Intellia Therapeutics (NTLA) and Editas Medicine (EDIT) in the CRISPR-Cas9 gene editing space beg the question – what a… Continue reading
Medical XpressNew gene therapy transplantation technique could improve treatment of neurodegenerative diseasesMedical XpressA study published today in Science Advances shows for the first time the efficacy of a new gene therapy transplantation techniqu… Continue reading
Drug Discovery & Development |
Immunovaccine Announces Positive Clinical Data from Collaborative Combination Immunotherapy Trial in Advanced …
Drug Discovery & Development Immunovaccine Inc, a clinical stage immuno-oncology company, announced positive top-line clinical data from its ongoing Phase 1b trial evaluating the safety and efficacy of Immunovaccine’s lead immuno-oncology candidate, DPX-Survivac, in combination … |
Jefferson Public Radio |
Stem Cell Therapy For You And For Fido
Jefferson Public Radio You’ve heard plenty about research into the use of stem cells to heal humans. But our pets, too? Yep… stem cells show just as much promise in treating the ailments of dogs as in people. Animal Cell Therapies is running trials, with the help of vet … |
Nikkei Asian Review |
Stem cell pioneer asks Fujifilm to keep licensing fees low
Nikkei Asian Review A licensing company called iPS Academia Japan manages the basic patents on iPS cell technology held by Kyoto University. For businesses, it sets royalties at just 1.5% of product sales. The low price is aimed at promoting the technology’s use, in … |